Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors

1. Ulisse S, Baldini E, Sorrenti S, D’Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009; 9: 32-71.10.2174/156800909787314002Search in Google Scholar

2. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 1998; 13: 893-906.10.3892/ijo.13.5.893Search in Google Scholar

3. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 2000; 12: 621-8.10.1016/S0955-0674(00)00141-1Search in Google Scholar

4. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-43.10.1038/nrm977Search in Google Scholar

5. Rosenberg S. The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective. Curr Pharm Des 2003; 9: 4p.10.2174/138161281030900ivSearch in Google Scholar

6. Reuning U, Sperl S, Kopitz C, Kessler H, Kruger A, Schmitt M, et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 2003; 9: 1529-43.10.2174/1381612033454612Search in Google Scholar

7. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.10.1093/jnci/94.2.116Search in Google Scholar

8. Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. for the German chemo N0 study group. Randomyzed adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.10.1093/jnci/93.12.913Search in Google Scholar

9. Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009; 148: 43-66.10.1007/978-0-387-79962-9_4Search in Google Scholar

10. Takac I, Cufer T, Gorisek B, Cas-Sikosek N, Bali R, Bosilj D, et al. [The role of the urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer]. [Slovenian]. Zdrav Vestn 2011; 80: 405-12.Search in Google Scholar

11. Duffy MJ, O’Grady P, Devaney D, O’Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988; 62: 531-3.10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-BSearch in Google Scholar

12. Jänicke F, Schmitt M, Ulm K, Gossner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989; 2: 1049.10.1016/S0140-6736(89)91070-2Search in Google Scholar

13. Foekens JA, Schmitt M, Van Putten WL, Peters HA, Bontenbal M, Jänicke F, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101-5.Search in Google Scholar

14. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12: 1648-58.10.1200/JCO.1994.12.8.1648Search in Google Scholar

15. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-43.Search in Google Scholar

16. Jelisavac-Cosic S, Sirotkovic-Skerlev M, Kulic A, Jakic-Razumovic J, Kovac Z, Vrbanec D. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study. Tumori 2011; 97: 532-9.10.1177/030089161109700419Search in Google Scholar

17. Eljuga D, Razumovic JJ, Bulic K, Petrovecki M, Draca N, Bulic SO. Prognostic importance of PAI-1 in node negative breast cancer patients - results after 10 years of follow up. Pathol Res Pract 2011; 207: 290-4.10.1016/j.prp.2011.02.008Search in Google Scholar

18. Gazic B, Pizem J, Bracko M, Cufer T, Borstnar S, Pohar-Marinsek Z, et al. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients. Cytopathology 2008; 19: 294-302.10.1111/j.1365-2303.2007.00528.xSearch in Google Scholar

19. Borstnar S, Sadikov A, Mozina B, Cufer T. High levels of uPA and PAI-1 predict a good response to anthracyclines. Breast Cancer Res Treat 2010; 121: 615-24.10.1007/s10549-009-0691-8Search in Google Scholar

20. Xu FJ, Stack S, Boyer C, O’Briant K, Whitaker R, Mills GB, et al. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 1997; 3: 1629-34.Search in Google Scholar

21. Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL, Ethier SP. ERBB-2 overexpression confers PI 3′ kinase-dependent invasion capacity on human mammary epithelial cells. Br J Cancer 2000; 82: 666-74.10.1054/bjoc.1999.0979Search in Google Scholar

22. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998; 273: 28238-46.10.1074/jbc.273.43.28238Search in Google Scholar

23. Arboleda J, Slamon DJ. Heregulin induced cell invasion of HER-2/neu transfected breast cancer cell line is mediated through activation of the phosphatidylinositol 3-kinase/AKT2 pathway. Cold Spring Harbor Laboratory Meeting on Tyrosine Phosphorylation and Cell Signaling; 1999 May 12.-16. p. 11.Search in Google Scholar

24. Berney CR, Yang J, Fisher RJ, Russell PJ, Crowe PJ. Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. Oncol Res 1998; 10: 47-54.Search in Google Scholar

25. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000; 18: 2201-9.10.1200/JCO.2000.18.11.2201Search in Google Scholar

26. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-66.10.1016/S0065-230X(08)60028-7Search in Google Scholar

27. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemostasis 1997; 78: 285-96.10.1055/s-0038-1657541Search in Google Scholar

28. Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003; 21: 1022-8.10.1200/JCO.2003.04.17012637466Search in Google Scholar

29. Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, et al. HER2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 2001; 7: 2448-57.Search in Google Scholar

30. Decker T, Hungermann D, Böcker W. [Prognostic and predictive factors of invasive breast cancer: update 2009]. [German]. Pathologe 2009; 30: 49-55.10.1007/s00292-008-1105-019184022Search in Google Scholar

31. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, eds. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone; 1987. p. 300-11.Search in Google Scholar

32. Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: six-year median follow-up. Br J Cancer 1999; 80: 419-26.10.1038/sj.bjc.6690373236231310408848Search in Google Scholar

33. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, et al. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer 1997; 76: 306-11.10.1038/bjc.1997.38322240719252196Search in Google Scholar

34. Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, et al. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 1999; 54: 147-57.10.1023/A:1006118828278Search in Google Scholar

35. Cufer T, Vrhovec I, Borštnar S. Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival. Int J Biol Mark 2002; 17: 33-41.10.1177/172460080201700104Search in Google Scholar

36. Cufer T, Vrhovec I, Borštnar S. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 and PAI-2 in operable breast cancer. Int J Biol Mark 2003; 18: 106-15.10.1177/172460080301800203Search in Google Scholar

37. Cufer T. Clinical utility of serine proteases in breast cancer. Radiol Oncol 2004; 38: 85-92.Search in Google Scholar

38. Ferrero-Poüs M, Hacene K, Bouchet C, Le Doussal V, Tubiana-Hulin M, Spyratos F. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000; 6: 4745-54.Search in Google Scholar

39. Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, et al. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. Clin Breast Cancer 2008; 4: 168-77.10.3816/CBC.2008.n.01818621614Search in Google Scholar

40. Harbeck N, Kates R, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-7.10.1200/JCO.2002.20.4.100011844823Search in Google Scholar

41. Esteva FJ, Hortobagyi GN. Prognostic markers in early breast cancer. Breast Cancer Res 2004; 6: 109-18.10.1186/bcr77740067415084231Search in Google Scholar

42. De Cremoux P, Grandin L, Diéras V, Savignoni A, Degeorges A, Salmon R, et al. Breast Cancer Study Group of the Institut Curie. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Res 2009; 29: 1475-82.Search in Google Scholar

43. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. J Natl Cancer Inst 2006; 98: 262-72.10.1093/jnci/djj05216478745Search in Google Scholar